sefulness of micafungin in the empiric therapy of invasive fungal infections in surgery and intensive-care medicine

Not Applicable

• Conditions: Patients undergoing gastroenterological surgery

• Registration Number: JPRN-UMIN000011388
• Lead Sponsor: Department of infectious disease, Hiroshima University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with a history of drug allergy against micafungin. 2. Patients with severe hepatic dysfunction. (bilirubin concentrations three times or ALT or AST five times the upper limit of the normal reference range)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. The efficacy of micafungin in patients with a proven or probable invasive fungal infection is evaluated on the 14th day (initial assessment) and at the end of dosing (final assessment). 2. The efficacy of micafungin in patients with a possible invasive fungal infection is evaluated on the 7th day (initial assessment) and at the end of dosing (final assessment).

Secondary Outcome Measures

Name	Time	Method
1. Persistence rate of micafungin administration 2. Adverse event during micafungin administration and follow-up 3. Mortality rate during micafungin administration 4.Susceptibility of isolated Candida spp.